Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 143
- Registration Number
- NCT00824408
- Locations
- ๐จ๐ฆ
1230.5.00106 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada
๐ง๐ธ1230.5.00118 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
๐จ๐ฆ1230.5.00114 Boehringer Ingelheim Investigational Site, Kelowna, British Columbia, Canada
Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 245
- Registration Number
- NCT00819091
- Locations
- ๐ฎ๐ณ
1218.35.91003 Boehringer Ingelheim Investigational Site, Aligarh, Uttar Pradesh, India
๐ฎ๐ณ1218.35.91006 Boehringer Ingelheim Investigational Site, Pune, Maharastra, India
๐ต๐ฑ1218.35.48003 Boehringer Ingelheim Investigational Site, Poznan, Poland
Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
- Conditions
- Heart Catheterization
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT00818753
- Locations
- ๐ณ๐ฑ
1160.73.31003 Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands
๐ณ๐ฑ1160.73.31002 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands
๐ณ๐ฑ1160.73.31004 Boehringer Ingelheim Investigational Site, Alkmaar, Netherlands
Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 445
- Registration Number
- NCT00819052
- Locations
- ๐บ๐ธ
1100.1526.1012 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States
๐ซ๐ท1100.1526.3306A Boehringer Ingelheim Investigational Site, Bobigny, France
๐ซ๐ท1100.1526.3304A Boehringer Ingelheim Investigational Site, Nice cedex 3, France
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
- Conditions
- Asthma
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 226
- Registration Number
- NCT00818454
- Locations
- ๐บ๐ธ
1012.57.114 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
๐บ๐ธ1012.57.143 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
๐บ๐ธ1012.57.134 Boehringer Ingelheim Investigational Site, Centennial, Colorado, United States
Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 83
- Registration Number
- NCT00809133
- Locations
- ๐ฌ๐ง
1200.12.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
๐ฌ๐ง1200.12.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5897
- Registration Number
- NCT00808067
- Locations
- ๐บ๐ธ
1160.71.0119 Boehringer Ingelheim Investigational Site, Tupelo, Mississippi, United States
๐บ๐ธ1160.71.0038 Boehringer Ingelheim Investigational Site, Hot Springs, Arkansas, United States
๐บ๐ธ1160.71.0482 Boehringer Ingelheim Investigational Site, Guilford, Connecticut, United States
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 718
- Registration Number
- NCT00806819
- Locations
- ๐บ๐ฆ
Boehringer Ingelheim Investigational Site, Vinnytsia, Ukraine
Surveillance Cohort Long-term Toxicity Antiretrovirals in HIV-infected Patients Enrolled in TPV Cohort
- Conditions
- HIV Infections
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT00805857
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
- First Posted Date
- 2008-12-09
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 180
- Registration Number
- NCT00804856
- Locations
- ๐ซ๐ท
HOP Edouard Herriot, Lyon Cedex 03, France
๐จ๐ฆMontreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada
๐ซ๐ทHOP Clรฉmenceau, Hรฉmato, Caen, Caen, France